Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases.
Eun-Jae LeeYoung-Min LimSeungmi KimLynkyung ChoiHyunjin KimKeonwoo KimHye Weon KimJi Sung LeeKwang-Kuk KimPublished in: Annals of clinical and translational neurology (2020)
The degrees to which serum NfL and GFAP levels reflect disease severity vary significantly with patient age in NMOSD, but not in MS. These findings suggest that the pathological processes and progression differ between the diseases; hence, serum biomarker levels may need to be interpreted differently according to patient age and disease type.